Selonsertib-Eluting Electrode Coating Attenuates Cochlear Injury Pathways

This study demonstrates that a novel selonsertib-eluting polymer coating on cochlear implant electrodes effectively mitigates acute tissue damage by inhibiting apoptosis and inflammation while promoting cell survival, thereby establishing a proof of concept for targeted drug delivery to improve device performance and longevity.

The Gist

The Big Picture: Fixing the "Scab" Problem

Imagine you have a Cochlear Implant. Think of this device as a high-tech hearing aid that bypasses damaged parts of your ear and sends electrical signals directly to your brain. It's like installing a new antenna on a radio to pick up a clear signal again.

However, there's a problem. When a surgeon inserts this "antenna" (the electrode) into the delicate inner ear, it's like driving a nail into a piece of fine wood. The wood gets damaged, and your body's natural reaction is to panic. It sends in the "construction crew" (immune cells) to fix the damage.

The Problem: Instead of just patching the hole, the construction crew goes overboard. They build a thick, hard wall of scar tissue (fibrosis) around the electrode.

• The Analogy: Imagine trying to listen to a radio, but someone wraps the antenna in layers of concrete. The signal gets weak, the sound becomes fuzzy, and eventually, the radio might stop working entirely. In the ear, this scar tissue blocks the electrical signals, reduces sound quality, and can even push the device out.

The Solution: A "Smart Coating" with a Healing Drug

The researchers in this paper wanted to stop the body from building that concrete wall. They decided to coat the electrode with a special "smart skin" that slowly releases a medicine called Selonsertib.

Think of this coating like a slow-release first-aid patch. Instead of just sitting there, it gently drips medicine onto the wound every day for a month.

What does the medicine do?
Selonsertib is a "brake pedal" for the body's stress response. When the ear is injured, a specific alarm system (called ASK1) goes off, screaming "DANGER!" This alarm triggers three bad things:

1. Cell Suicide: Healthy cells kill themselves.
2. Inflammation: The area gets red, swollen, and angry.
3. Fibrosis: The body builds that thick scar tissue wall.

Selonsertib turns off the alarm, stopping the suicide, calming the anger, and preventing the concrete wall from forming.

How They Tested It (The Lab Experiment)

Since they couldn't just test this on people immediately, they used a clever lab setup:

1. The Fake Electrodes: They took thin wires (mimicking the implant) and dipped them in a special plastic (PCL) mixed with the medicine. They built up layers of this plastic until it was the right thickness—like dipping a stick in chocolate to make a candy bar.
2. The "Ear in a Cup": They took tiny pieces of mouse inner ear tissue (cochlear explants) and floated them in a liquid culture.
   • Group A: Got liquid with just the plastic coating (no medicine).
   • Group B: Got liquid with the plastic coating releasing Selonsertib.
   • Group C: Got liquid with the medicine added directly (to check if the drug still worked after being trapped in plastic).
3. The Stress Test: To make sure the medicine was strong, they also added a toxic chemical (neomycin) to some cups to simulate a severe injury, like a loud noise or a bad infection.

What They Found (The Results)

The researchers used a super-powerful microscope (Mass Spectrometry) to look at the proteins inside the ear cells. It's like taking a snapshot of every single worker in a factory to see what they are doing.

The Findings:

• The Plastic was Safe: The plastic coating itself didn't hurt the cells. It was like a neutral wrapper.
• The Medicine Worked Wonders: The ear cells exposed to the Selonsertib coating looked much healthier.
  • Less "Suicide": Fewer cells were dying.
  • Less "Anger": The inflammation signals were turned down.
  • No "Concrete Wall": The proteins that build scar tissue were significantly reduced.
• Even in a Crisis: When they added the toxic chemical (the "stress test"), the Selonsertib group still survived much better than the others. It was like having a superhero shield that protected the cells even when things got really bad.

Why This Matters

This study is a proof-of-concept. It proves that:

1. We can successfully coat an electrode with this drug.
2. The drug stays active and works inside the ear.
3. It stops the body from building the scar tissue that ruins hearing implants.

The Future:
If this works in humans, it could mean that cochlear implants last longer, work better, and provide clearer sound for the rest of the recipient's life. It's like upgrading a car's engine so it doesn't rust out after a few years.

Furthermore, because this drug is already known to be safe for humans (it's been tested for liver disease), this technology could move from the lab to the clinic relatively quickly. It might also be used for other implants, like pacemakers or brain electrodes, wherever scar tissue is a problem.

Summary in One Sentence

The researchers created a special "healing skin" for cochlear implants that slowly releases a drug to stop the body from building scar tissue, ensuring the device works clearly and lasts longer.

Technical Summary

1. Problem Statement

Cochlear implants (CIs) are transformative devices for severe-to-profound hearing loss, yet their long-term efficacy is compromised by the body's biological response to surgical trauma.

• The Issue: Electrode insertion causes acute tissue damage, triggering apoptosis (cell death), inflammation, and the foreign body response.
• Consequences: This leads to fibrotic encapsulation around the electrode (occurring in 95–100% of cases), which increases electrical impedance, degrades sound quality, and can cause device failure or extrusion.
• Current Limitations: Existing drug-eluting coatings primarily deliver neurotrophins or dexamethasone. While effective, they do not fully address the complex interplay of apoptosis, inflammation, and extracellular matrix (ECM) remodeling driven by upstream signaling pathways.
• Therapeutic Gap: There is a need for a targeted therapeutic strategy that inhibits the master regulator of these stress responses to preserve residual hearing and prevent fibrosis.

2. Methodology

The study employed a multi-disciplinary approach combining material science, pharmacology, and advanced proteomics.

• Material Development:

  • Drug: Selonsertib, an inhibitor of Apoptosis Signal-regulating Kinase 1 (ASK1), known for anti-inflammatory and anti-fibrotic properties.
  • Polymers: Polycaprolactone (PCL) and Polyethylene vinyl acetate (PEVA) were selected for their biocompatibility and ability to encapsulate hydrophobic drugs.
  • Fabrication: Dummy electrodes (silicon filaments) were dip-coated with 1, 3, 5, or 10 layers of drug-loaded or control polymers.
  • Characterization: Scanning Electron Microscopy (SEM) was used to assess coating morphology and thickness. High-Performance Liquid Chromatography (HPLC) quantified drug release kinetics over 28 days in both static and dynamic (daily media change) conditions.

• Biological Model:

  • Ex Vivo System: Mouse cochlear explants (P3 pups) were cultured for 24 hours.
  • Pre-conditioning: Explants were cultured in media pre-conditioned for 28 days by submerged coated electrodes (Selonsertib-PCL, PCL-only control, or uncoated control).
  • Stress Models: Two conditions were tested:
    1. Dissection-only: To model acute surgical trauma.
    2. Neomycin-treated: To model intensified ototoxic injury (1 mM neomycin).

• Proteomic Analysis:

  • Technique: Next-generation mass spectrometry (Orbitrap Astral) coupled with Data-Independent Acquisition (DIA).
  • Scope: Quantitative analysis of ~7,700 protein groups in cochlear explants and ~1,700 proteins in the secretome (culture media).
  • Data Processing: Differential abundance analysis using limma, followed by Gene Set Enrichment Analysis (GSEA) for pathways (Reactome, GO).

3. Key Contributions

• Novel Drug Delivery System: Development and validation of a selonsertib-eluting polymer coating capable of sustained release over 28 days.
• Mechanistic Insight via Proteomics: Moving beyond simple cell viability assays, the study utilized deep proteomic profiling to map the specific molecular pathways attenuated by ASK1 inhibition in the cochlea.
• Dual-Target Hypothesis: The data suggests selonsertib may exert therapeutic effects not only through ASK1 inhibition but potentially via secondary inhibition of CDK6, offering a broader mechanism for cytoprotection.
• Secretome Characterization: Detailed mapping of the secreted protein profile, demonstrating that the treatment reduces the secretion of pro-fibrotic and pro-inflammatory signals that drive the foreign body response.

4. Key Results

• Material Characterization:

  • PCL and PEVA formed uniform, porous coatings.
  • Release Kinetics: PCL coatings released significantly more selonsertib (1 µM/day) than PEVA. PCL exhibited an initial burst release followed by sustained release, maintaining concentrations above the human EC50 (0.1 µM) for 28 days.
  • Biocompatibility: PCL-only coatings showed no significant molecular changes compared to controls, confirming the polymer itself is inert.

• Proteomic Findings (Dissection Model):

  • Anti-Fibrotic Effect: Selonsertib treatment significantly downregulated ECM and fibrosis-associated proteins (e.g., IGFBP2, CCN2, LOXL2, SFRP1/2).
  • Anti-Inflammatory/Anti-Apoptotic: Upregulation of pro-survival proteins (MCL1, MAP3K1, NDUFA4) and downregulation of pro-apoptotic factors (DKK2, DKK3, HEXIM1).
  • Pathway Interruption: The data indicates the interruption of the WNT-TGF-β-SMAD feedback loop, a master regulator of fibrosis.

• Proteomic Findings (Neomycin/Ototoxicity Model):

  • Selonsertib maintained efficacy under severe stress, suppressing additional apoptotic markers (e.g., TF for ferroptosis, ENDOG for mitochondrial apoptosis).
  • Upregulation of stress-adaptive antioxidants (HMOX1, FTL1) was observed.
  • A shared signature of 16 downregulated proteins (including STAT6, COL16A1, IGFBP2) was found across both injury models, confirming a robust protective mechanism.

• Secretome Analysis:

  • Selonsertib-treated explants secreted significantly fewer immune recruitment signals (e.g., PRSS23, SPON2) and ECM deposition factors (e.g., COL1A2, IGFBP3).
  • This suggests a systemic reduction in the signals that recruit fibroblasts and drive encapsulation.

5. Significance and Implications

• Clinical Translation: This study provides a "proof-of-concept" for a clinically translatable strategy. Selonsertib has already passed Phase I-III trials for other indications (demonstrating safety and tolerability), and PCL is a biocompatible material already used in biomedical devices.
• Improved CI Outcomes: By mitigating fibrosis and preserving spiral ganglion neurons, this coating could extend device longevity, improve speech perception (by lowering impedance), and reduce the need for revision surgeries.
• Broader Applicability: The strategy is not limited to cochlear implants; it could be adapted for other neural electrodes, cardiac devices, and ophthalmic implants where fibrotic encapsulation is a limiting factor.
• Oncology Repurposing: The unexpected upregulation of cell-cycle proteins and the potential dual inhibition of CDK6 suggest selonsertib could be repurposed to protect against ototoxicity in cancer patients undergoing chemotherapy, or conversely, used to inhibit tumor growth while protecting the ear.

In conclusion, the paper demonstrates that a selonsertib-eluting PCL coating effectively attenuates the acute molecular pathways of cochlear injury, offering a promising, multi-targeted solution to the chronic problem of fibrosis in cochlear implantation.